1929 Hanpei Sawai and Noyo Sawai established Sawai Pharmacy in Asahi-ku, Osaka.
1948 Sawai Pharmaceutical Co., Ltd. incorporated in Asahi-ku, Osaka with a capital of 195,000 yen.
1955 Tokyo Branch Office (now Tokyo Branch) opened.
1961 Manufacturing lines for OTC drugs set up in the factory of head office.
1962 Process patent on the extraction of garlic acquired and YORON P and ARIARON launched.
Ethical pharmaceutical market entered into.
Sapporo Sales Office (now Sapporo Branch), Tohoku Sales Office (now Sendai Branch), Nagoya Sales Office (now Nagoya Branch), and Fukuoka Sales Office (now Fukuoka Branch) opened.
1965 Operations shifted from OTC drugs maker to ethical pharmaceutical maker.
1968 Osaka Factory No. 2 (now Osaka Factory) completed.
1974 Former company head office building completed and head office relocated.
1979 Hiroshima Sales Office (now Hiroshima Branch) opened.
1981 First stage of construction of Kyushu Factory completed (antibiotic production facilities).
1983 Second stage of construction of Kyushu Factory completed (general medication and syrup production facilities).
1984 Osaka Laboratory opened to expand and improve research facilities.
1985 Medisa Shinyaku Inc. incorporated.
Third stage construction of Kyushu Factory completed (injectable production facilities).
1987 First stage of construction of Medisa Shinyaku Inc. Kyushu Factory completed (general medication production and other facilities).
1989 Fourth stage of construction of Kyushu Factory completed (expanded injectable production and other facilities).
1990 Research & Development Center established to enhance research and development functions.
Osaka Branch opened.
1991 Medisa Shinyaku Inc. set up as a wholly owned subsidiary.
1992 Second stage of construction of Medisa Shinyaku Inc. Kyushu Factory completed (packaging facilities).
First stage of construction of Sanda Factory completed (general medication production facilities).
1994 Former Pharmaceutical Research Center opened to improve pharmaceutical research.
1995 Listed on the OTC stock market.
1996 Third stage of construction of Medisa Shinyaku Inc. Kyushu Factory completed (Quality Control Analysis Laboratory and other facilities).
1997 Newspaper advertising started.
Fourth and fifth stages of construction of Medisa Shinyaku Inc. Kyushu Factory completed (general medication production facilities and expanded automated warehousing).
2000 Production facilities for injections expanded in Kyushu Factory.
Listed on the second section of the Tokyo Stock Exchange.
2002 Fifth stage of construction of Kyushu Factory completed (oral sustained-release agent production and packaging facilities).
2003 Listed on the first section of the Tokyo Stock Exchange.
2004 New VIS (Visual Identity System) installed.
Nationwide TV advertising started.
2005 Second stage of construction of Sanda Factory completed (expanded general medication production facilities and specialist medication production facilities).
Kanto Factory transferred from Nihon Schering K.K.
2006 Sumitomo Corporation Group became an investor in Medisa Shinyaku Inc.
Head office and Research laboratories combined, and new premises completed. Relocated to current premises.
Became majority shareholder in Kaken Shoyaku Inc. and made the company into a subsidiary.
2007 New building for syringe production established in Kanto Factory.
Kumamoto Sales Office and Okayama Sales Office opened.
2008 Sixth stage of construction of Medisa Shinyaku Inc. Kyushu Factory completed (expanded oral solid medication production and other facilities).
Hiroyuki Sawai appointed to chairman and Mitsuo Sawai appointed to president.
2009 Third stage of construction of Sanda Factory completed (expanded general medication production facilities).
Sales Promotion Department relocated to Tokyo.
Saitama Branch opened. Moved to system of 8 branches and 11 sales offices nationwide.
Pharmaceutical Technology Center opened.



 
About Us IR Information